文献速递肝病

失代偿期肝硬化患者多疗程粒细胞集落刺激因子联合或不联合生长激素治疗的结局:一项随机试验

Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial.
PubMed 文献 · Hepatology · 2018-07-25

65例失代偿期肝硬化患者随机分为标准药物治疗联合每3月一次粒细胞集落刺激因子并每日生长激素组(A组,n=23)、标准药物治疗联合粒细胞集落刺激因子组(B组,n=21)或单用标准药物治疗组(C组,n=21)。A组和B组12个月无移植生存率显著优于C组(P=0.001),且CD34+细胞较基线升高(P<0.001),临床评分、营养、腹水控制、肝硬度、感染发作和生活质量均较基线改善(P<0.05)。生长激素未显示额外获益。

要点

  • 多疗程粒细胞集落刺激因子可改善失代偿期肝硬化患者12个月无移植生存率。
  • 粒细胞集落刺激因子联合或不联合生长激素均较基线改善临床评分、营养、腹水控制、肝硬度、感染和生活质量。
  • 联合生长激素较单用粒细胞集落刺激因子未显示额外获益。

核心结论

  • 多疗程粒细胞集落刺激因子可改善失代偿期肝硬化患者12个月无移植生存率、动员造血干细胞、改善疾病严重程度评分、营养、纤维化、生活质量评分、腹水控制、减少感染和肝移植需求。
  • 联合使用生长激素未发现任何额外获益。

研究设计与样本

  • 随机试验,纳入65例失代偿期肝硬化患者。
  • 患者随机分为标准药物治疗联合每3月一次粒细胞集落刺激因子并每日生长激素组(A组,n=23)、标准药物治疗联合粒细胞集落刺激因子组(B组,n=21)或单用标准药物治疗组(C组,n=21)。
  • 主要结局为12个月无移植生存率。
  • 次要结局为第6天CD34+细胞动员情况及12个月时临床评分、肝硬度、营养、感染发作和生活质量的改善。

主要发现

  • A组和B组12个月无移植生存率显著优于C组(P=0.001)。
  • 治疗第6天,A组和B组CD34+细胞较基线升高(P<0.001)。
  • 12个月时,A组和B组临床评分显著下降、营养改善、腹水控制更好、肝硬度降低、感染发作更少、生活质量评分改善,均较基线有显著差异(P<0.05)。
  • 治疗耐受性良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Decompensated cirrhosis (DC) carries a high mortality. Liver transplantation (LT) is the treatment of choice; however, the limited availability of donor organs has resulted in high waitlist mortality. The present study investigated the impact of multiple courses of granulocyte-colony stimulating factor (G-CSF) with or without growth hormone (GH) in these patients. Sixty-five patients with DC were randomized to standard medical therapy (SMT) plus G-CSF 3 monthly plus GH daily (group A; n = 23) or SMT plus G-CSF (group B; n = 21) or SMT alone (group C; n = 21). The primary outcome was transplant-free survival (TFS) at 12 months. Secondary outcomes were mobilization of CD34+ cells at day 6 and improvement in clinical scores, liver stiffness, nutrition, episodes of infection, and quality of life (QOL) at 12 months. There was significantly better 12-month TFS in groups A and B than in group C (P = 0.001). At day 6 of therapy, CD34+ cells increased in groups A and B compared to baseline (P < 0.001). There was a significant decrease in clinical scores, improvement in nutrition, better control of ascites, reduction in liver stiffness, lesser infection episodes, and improvement in QOL scores in groups A and B at 12 months as compared to baseline (P < 0.05). The therapies were well tolerated. CONCLUSION: Multiple courses of G-CSF improved 12-month TFS, mobilized hematopoietic stem cells, improved disease severity scores, nutrition, fibrosis, QOL scores, ascites control, reduced infections, and the need for LT in patients with DC. However, the use of GH was not found to have any additional benefit. (Hepatology 2017).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Verma N, Kaur A, Sharma R, et al. Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial. Hepatology. 2018. PMID: 29278428. doi:10.1002/hep.29763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。